Montreal Heart Institute Colcorona Study receives grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation to investigate cheap, readily available drug
Summary
As this low-cost common gout drug presents itself as a potential treatment to fight coronavirus, this recognition by the Foundation will enable MHI to bring this research to a greater number of people affected by COVID-19, especially in areas where the population is more vulnerable due to health and economic inequities. “ColCorona exemplifies how we can look to bring scientific breakthroughs in a time- and cost-effective manner to patients by repurposing older drugs,” said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and ColCorona primary investigator. It was initiated by Dr. Jean-Claude Tardif, Director of the MHI Research Center and Professor of Medicine at the University of Montreal and aims to determine if colchicine may prevent the phenomenon of major inflammatory storm observed in adults suffering from serious complications linked to COVID-19. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private, full-service pharmaceutical company with deep roots in Canada, and whose global reach is growing, in part thanks to the distribution of its products in more than 60 countries. www.cgi.com/canada Note to media: ColCorona Clinical Trial is available in Montreal, New York Tri State Area (NYU Langone), New Jersey and Connecticut, California (UCSF), Madrid (Spain), British Columbia, Ontario and Alberta.
Classifications
AskAI Classifications
LabelsLinked Companies
